Treatment outcomes with long acting octreotide in inoperable hepatocellular carcinoma: A local experience and review of literature

Journal of the Pakistan Medical Association

Volumn 55, Issue 4, 2005, Pages 135-138

  Gill, Muzaffar Lateef ^a   Atiq, Muslim ^a   Sattar, Syma ^a   Khokhar, Nasir ^a  

^a SHIFA INTERNATIONAL HOSPITAL   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; OCTREOTIDE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFORMED CONSENT; INOPERABLE CANCER; LIVER CELL CARCINOMA; MALE; MEDICAL LITERATURE; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; SOCIOECONOMICS; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR VOLUME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; LIVER TUMOR; MIDDLE AGED; SURVIVAL;

ANTINEOPLASTIC AGENTS, HORMONAL; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; OCTREOTIDE; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23844548642     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Scudamore CH, Ragaz J, Kluftinger AM, Owen DA. Hepatocellular carcinoma: a comparison of oriental and Caucasian patients. Am J Surg 1988;155:659-62.
2. Wong F, Choi TK. Primary liver cell cancer. Asian experience. In: Blumgart LH (ed). Surgery of liver and biliary tract. London: Churchill Livingstone, 1988, pp. 1135-51.
3. Mujeeb SA, Jamal Q, Khanani R, Iqbal N, Kaher S. Prevalence of hepatitis B surface antigen and HCV antibodies in hepatocellular carcinoma cases in Karachi, Pakistan. Trop Doct 1997;27:45-6.
4. Qureshi H, Zuberi SJ, Jafarey NA, Zaidi SH. Hepatocellular carcinoma in Karachi. J Gastroenterol Hepatol 1990;5:1-6.
5. Tong CY, Khan R, Beeching NJ, Tariq WU, Hart CA, Ahmad N, et al. The occurrence of hepatitis B and C viruses in Pakistani patients with chronic liver disease and hepatocellular carcinoma. Epidemiol Infect 1996;117:327-32.
6. Mannesis EK, Giannoulis G, Zoumpoulis P, Vafiadou I, Hadjiyannis SG. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995;21:1535-42.
7. Chao Y, Chan WK, Huang YS, Teng HC, Wang SS. Phase II of flutamide in the treatment of hepatocellular carcinoma. Cancer 1996;77:635-9
8. Ram AM, Bhattacharya S, Novell JR, Dick R, Winslet MC, Hobbs KEF. Intra-arterial radiotherapy with 131 iodine-lipiodol for irresectable hepatocellular carcinoma(abstract). Gut 1996;38 (suppl 1):A17.
9. Madden MV, Krige JEJ, Bailey S, Beningfield SJ, Geddes C, Werner FD, et al. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 1993;34:1598-1600.
10. Rossi P, Rossi M, Clementi M, Pizzamiglio M, Bezzi M, Salvatori FM. Chemoembolization of hepatocellular carcinomas. Proceedings, European seminars on diagnostic and interventional radiology. Heraklion: 1994, pp. 315-20.
11. Bhattacharya S, Novell JR, Dusheiko GM, Hilson AJ, Dick R, Hobbs KE. Epirubicin-lipiodol chemotherapy versus 131 iodine-lipiodol radiotherapy in the treatment of unresectable hepatocellular carcinoma. Cancer 1995;76:2202-10.
12. Lamberts SWJ, Van Der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996;334:246-54.
13. Reubi JC, Kvols L, Krenning E, Lamberts SWJ. Distribution of somatostatin receptors in normal and tumour tissue. Metabolism 1990;39(Suppl 2):78-81.
14. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogues in the diagnosis and treatment of tumours. Endocr Rev 1991;12:450-82.
15. Kouroumalis E, Skordilis P, Thermos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7.
16. Khokhar N, Aijazi I, Gill ML. Spectrum of hepatocellular carcinoma at Shifa International Hospital, Islamabad. J Ayub Med Coll 2003;15:1-4.
17. Rehman AU, Murad S. Hepatocellular carcinoma: a retrospective analysis of 118 cases. J Coll Phys Surg Pak 2002;12:108-9.
18. Butt A, Khan A, Alam A, Ahmad S, Shah S, Shafqat F, et al. Hepatocellular carcinoma: analysis of 76 cases. J Pak Med Assoc 1998;48:197-201.
19. Shah HA, Jafri W, Malik I, Prescott L, Simmonds P. Hepatitis C virus (HCV) genotypes in Pakistan. J Gastroentrol Hepatol 1997;12:758-61.
20. Sharieff S, Burney I, Salam A, Siddiqui T. Hepatocellular carcinoma. J Coll Phys Surg Pak 2002;12:264-7.
21. Rabe C, Pilz T, Allgaier HP, Halm U, Strasser C, Wettstein M, et al. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Z Gastroenterol. 2002;40:395-400.
22. Yuen MF, Poon RTP, Lai CL, Fan ST, Lo CM, Wong KW, et al. A randomized placebo-controlled study of long acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002 36:687-91.
23. Farooqi JI, Farooqi RJ. Efficacy of octreotide in cases of inoperable hepatocellular carcinoma: a clinical trial. J Coll Phys Surg Pak 2000;10:258-60.